Open AccessEvaluation of Appropriateness and Cost Savings of Pharmacist-Driven Palivizumab Ordering
Author(s) -
Krista L. Weaver,
Deborah S. Bondi,
Pooja Shah,
Palak Bhagat
Publication year - 2020
Publication title -
the journal of pediatric pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 15
eISSN - 2331-348X
pISSN - 1551-6776
DOI - 10.5863/1551-6776-25.7.636
Subject(s) - palivizumab , medicine , pharmacist , schedule , pediatrics , pharmacotherapy , vial , emergency medicine , pharmacy , family medicine , respiratory system , computer science , chemistry , operating system
Guidelines by the AAP for the use of palivizumab prophylaxis for respiratory syncytial virus (RSV) recommend administration within 72 hours prior to discharge for selected high-risk patient populations. Our institution historically administered palivizumab on a fixed-day schedule of Mondays and Thursdays, but adjusted the practice in fall 2017 to a pharmacist-driven flex-schedule based on anticipated discharge date. This review evaluated the effect of pharmacist-driven palivizumab ordering on the appropriateness of palivizumab administrations, based on AAP and institutional recommendations. Additionally, this review evaluated for effects on institutional cost.